Genovis
Business Services · Sweden · 11-50 Employees
View Company Info for Free
Overview
Headquarters
PO Box, Kävlinge, Skane, 24421, SwedenPhone Number
+46 46101230Website
www.genovis.comRevenue
$13 MillionStock Symbol
GENO.STIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Genovis
Genovis’ business concept is to provide customers in the biopharmaceutical and research industries with tools that facilitate and save time in the development of new treatment methods and diagnostics. The company’s enzyme products, known as SmartEnzymes, are used by scientists worldwide, and the innovative product formats support the development and quality control of biological drugs.Explore more
Genovis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Genovis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Genovis is spiking on competitors!
Check if Genovis has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Genovis launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Genovis
Funding: Get notified immidiatlly once Genovis has new funding data
Click to see if Genovis had a recent Job posting/layoffs
Earning: See what the market has to say on Genovis recently announced quarterly report
Genovis, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Genovis
Compare insights from companies similar to Genovis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Genovis is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Genovis is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Genovis.
Genovis Tech Stack
A closer look at the technologies used by Genovis
See more technologies
Most Recent Scoops
Event
Award, Video
Event
Events
Event
Events
Event
will be attending the 15th Annual PEGS Europe 2023 conference as an exhibitor. The event will occur from November 14 to November 16, 2023.
Events
Event
Events
Genovis News & Media
Leinco Technologies Inc. Acquires QED Biosciences, Leading Provider of Antibodies, Related Reagents, and Development Services
Strategic acquisition will enable Leinco to expand its portfolio of antibody capabilities used globally for research and diagnostics. ST. LOUIS, Sept. 3, 2024 /PRNewswire/ -- Leinco Technologies ("Leinco"), a trusted source of high-quality primary and secondary antibodies, recombinant...Genovis Announces Strategic Divestment of Antibody Business to Leinco Technologies Inc.
Genovis, a leading innovator in enzyme technology, today announced the successful divestment of its antibody business to Leinco Technologies Inc., a globally recognized developer of high-quality antibodies for research and diagnostics. This strategic move aligns with Genovis previously communicated focus on optimizing the core business operation and enhancing profitability. The divestment follows a strategic review by Genovis, which identified the need to concentrate on its core enzyme business—SEQURNA moving forward with industrial partner Genovis - Notified
The Swedish biotech company Genovis has invested and partnered with SEQURNA, a developer of next-generation RNase inhibitors.Genovis completes a strategic investment in SEQURNA, a developer of next-generation RNase inhibitors
This strategic investment unlocks new product offerings for Genovis to both existing and new customers and further paves the way for the expansion into new application areas. Genovis will utilize its distribution network to market and sell SEQURNA’s RNase inhibitors alongside its own catalogue of innovative tools for the biopharmaceutical and research industries. Following the investment, Genovis will own 25 percent of SEQURNA. As part of the transaction, the parties have agreed to a call
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Genovis
Sign Up For FreeTo access detailed company insights
Genovis’ business concept is to provide customers in the biopharmaceutical and research industries with tools that facilitate and save time in the development of new treatment methods and diagnostics. The company’s enzyme products, known as SmartEnzymes, are used by scientists worldwide, and the innovative product formats support the development an... Read More
